CV Therapeutics Overview

  • Year Founded
  • 1990

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 550

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.4B

CV Therapeutics General Information

Description

Developer and marketer of novel, small molecule drugs for the treatment of cardiovascular diseases. The company's major products were Ranexa (ranolazine extended-release tablets) and Lexiscan (regadenoson).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 3172 Porter Dr
  • Palo Alto, CA 94304
  • United States
+1 (650)
Primary Industry
Drug Discovery
Acquirer
Vertical(s)
Corporate Office
  • 3172 Porter Dr
  • Palo Alto, CA 94304
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CV Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 17-Apr-2009 $1.4B Completed Generating Revenue
8. PIPE 16-Apr-2008 Completed Generating Revenue
7. PIPE 18-Apr-2006 Completed Generating Revenue
6. PIPE 01-Aug-2000 Completed Generating Revenue
5. IPO 06-Oct-1999 Completed Generating Revenue
4. Later Stage VC (Series G) 01-May-1996 Completed Generating Revenue
3. Later Stage VC (Series E) 01-Nov-1995 Completed Generating Revenue
2. Later Stage VC (Series D) 01-Apr-1994 $16.5M $23.4M Completed Generating Revenue
1. Later Stage VC (Series C) 01-Jul-1993 $6.88M $6.88M Completed Generating Revenue
To view CV Therapeutics’s complete valuation and funding history, request access »

CV Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CV Therapeutics Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Acqua Wellington PE/Buyout Minority
Alloy Ventures Venture Capital Minority
Asset Management Ventures Venture Capital Minority
Axon Capital Hedge Fund Minority
Azimuth Opportunity Investment Bank Minority
You’re viewing 5 of 16 investors. Get the full list »

CV Therapeutics FAQs

  • When was CV Therapeutics founded?

    CV Therapeutics was founded in 1990.

  • Where is CV Therapeutics headquartered?

    CV Therapeutics is headquartered in Palo Alto, CA.

  • What is the size of CV Therapeutics?

    CV Therapeutics has 550 total employees.

  • What industry is CV Therapeutics in?

    CV Therapeutics’s primary industry is Drug Discovery.

  • Is CV Therapeutics a private or public company?

    CV Therapeutics is a Private company.

  • What is the current valuation of CV Therapeutics?

    The current valuation of CV Therapeutics is .

  • What is CV Therapeutics’s current revenue?

    The current revenue for CV Therapeutics is .

  • How much funding has CV Therapeutics raised over time?

    CV Therapeutics has raised $609M.

  • Who are CV Therapeutics’s investors?

    Acqua Wellington, Alloy Ventures, Asset Management Ventures, Axon Capital, and Azimuth Opportunity are 5 of 16 investors who have invested in CV Therapeutics.

  • When was CV Therapeutics acquired?

    CV Therapeutics was acquired on 17-Apr-2009.

  • Who acquired CV Therapeutics?

    CV Therapeutics was acquired by Gilead.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process